Halia’s $30M Series C; Windtree assesses ‘strategic’ options; LifeArc, Gates invest in Africa accelerator

Plus, news about Cor­bus and Astel­las:

Halia Ther­a­peu­tics rais­es $30M Se­ries C: The com­pa­ny, which is de­vel­op­ing small mol­e­cules for in­flam­ma­to­ry dis­eases, plans to use the fund­ing to progress its lead as­set through Phase II tri­als. HT-6184 tar­gets the NLP3 in­flam­ma­some.

Windtree Ther­a­peu­tics to con­sid­er ‘strate­gic al­ter­na­tives’: The biotech last week said Deer­field Man­age­ment had ter­mi­nat­ed rights to a deal it made with Windtree back in 2017. The com­pa­ny is now con­sid­er­ing li­cens­ing deals, M&A or a sale.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.